메뉴 건너뛰기




Volumn 31, Issue 41, 2013, Pages 4477-4486

Effectiveness of meningococcal serogroup C vaccine programmes

Author keywords

Children; Immunologic memory; Meningococcal serogroup C vaccine; Monovalent glycoconjugate vaccine; Vaccine effectiveness

Indexed keywords

MENINGOCOCCUS VACCINE; MENITORIX; UNCLASSIFIED DRUG;

EID: 84883598147     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.083     Document Type: Review
Times cited : (80)

References (71)
  • 3
    • 0033957876 scopus 로고    scopus 로고
    • Update on meningococcal disease with emphasis on pathogenesis and clinical management
    • van Deuren M., Brandtzaeg P., van der Meer J.W. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clinical Microbiology Reviews 2000, 13:144-166.
    • (2000) Clinical Microbiology Reviews , vol.13 , pp. 144-166
    • van Deuren, M.1    Brandtzaeg, P.2    van der Meer, J.W.3
  • 4
    • 34250795027 scopus 로고    scopus 로고
    • Epidemic meningitis, meningococcaemia, and Neisseria meningitidis
    • Stephens D.S., Greenwood B., Brandtzaeg P. Epidemic meningitis, meningococcaemia, and Neisseria meningitidis. Lancet 2007, 369:2196-2210.
    • (2007) Lancet , vol.369 , pp. 2196-2210
    • Stephens, D.S.1    Greenwood, B.2    Brandtzaeg, P.3
  • 6
    • 84883597359 scopus 로고    scopus 로고
    • European Centre for Disease Prevention and Control. Surveillance report on invasive bacterial disease in Europe for 2008-2009. European Centre for Disease Prevention and Control 2011 July 18. [accessed 22.03.13]
    • European Centre for Disease Prevention and Control. Surveillance report on invasive bacterial disease in Europe for 2008-2009. European Centre for Disease Prevention and Control 2011 July 18. [accessed 22.03.13]. http://www.ecdc.europa.eu/en/press/news/Lists/News/ECDC_DispForm.aspx%3FList=32e43ee8-e230-4424-a783-85742124029a%26ID=464%26RootFolder=%2Fen%2Fpress%2Fnews%2FLists%2FNews.
  • 7
    • 0035888124 scopus 로고    scopus 로고
    • Planning, registration, and implementation of an immunisation campaign against meninococcal serogroup C disease in the UK: a success story
    • Miller E., Salisbury D., Ramsay M. Planning, registration, and implementation of an immunisation campaign against meninococcal serogroup C disease in the UK: a success story. Vaccine 2001, 20(Suppl. 1):S58-S67.
    • (2001) Vaccine , vol.20 , Issue.SUPPL. 1
    • Miller, E.1    Salisbury, D.2    Ramsay, M.3
  • 8
    • 63849194065 scopus 로고    scopus 로고
    • Prevention of meningococcal serogroup C disease by NeisVac-C
    • Borrow R., Findlow J. Prevention of meningococcal serogroup C disease by NeisVac-C. Expert Review of Vaccines 2009, 8:265-279.
    • (2009) Expert Review of Vaccines , vol.8 , pp. 265-279
    • Borrow, R.1    Findlow, J.2
  • 9
    • 20444437173 scopus 로고    scopus 로고
    • Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain
    • Larrauri A., Cano R., García M., Mateo S. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Vaccine 2005, 23:4097-4100.
    • (2005) Vaccine , vol.23 , pp. 4097-4100
    • Larrauri, A.1    Cano, R.2    García, M.3    Mateo, S.4
  • 10
    • 0037442694 scopus 로고    scopus 로고
    • Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis
    • Ramsay M.E., Andrews N.J., Trotter C.L., Kaczmarski E.B., Miller E. Herd immunity from meningococcal serogroup C conjugate vaccination in England: database analysis. BMJ 2003, 326:365-366.
    • (2003) BMJ , vol.326 , pp. 365-366
    • Ramsay, M.E.1    Andrews, N.J.2    Trotter, C.L.3    Kaczmarski, E.B.4    Miller, E.5
  • 11
    • 3242768475 scopus 로고    scopus 로고
    • Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction
    • Trotter C.L., Andrews N.J., Kaczmarski E.B., Miller E., Ramsay M.E. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004, 364:365-367.
    • (2004) Lancet , vol.364 , pp. 365-367
    • Trotter, C.L.1    Andrews, N.J.2    Kaczmarski, E.B.3    Miller, E.4    Ramsay, M.E.5
  • 12
    • 33745271338 scopus 로고    scopus 로고
    • Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales
    • Trotter C.L., Edmunds W.J., Ramsay M.E., Miller E. Modeling future changes to the meningococcal serogroup C conjugate (MCC) vaccine program in England and Wales. Human vaccines 2006, 2:68-73.
    • (2006) Human vaccines , vol.2 , pp. 68-73
    • Trotter, C.L.1    Edmunds, W.J.2    Ramsay, M.E.3    Miller, E.4
  • 13
    • 67349179167 scopus 로고    scopus 로고
    • Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease
    • Frasch C.E., Borrow R., Donnelly J. Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. Vaccine 2009, 27(Suppl. 2):B112-B116.
    • (2009) Vaccine , vol.27 , Issue.SUPPL. 2
    • Frasch, C.E.1    Borrow, R.2    Donnelly, J.3
  • 14
    • 0342891343 scopus 로고    scopus 로고
    • Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group
    • Maslanka S.E., Gheesling L.L., LiButti D.E., Donaldson K.B., Harakeh H.S., Dykes J.K., et al. Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group. Clinical and Diagnostic Laboratory Immunology 1997, 4:156-167.
    • (1997) Clinical and Diagnostic Laboratory Immunology , vol.4 , pp. 156-167
    • Maslanka, S.E.1    Gheesling, L.L.2    LiButti, D.E.3    Donaldson, K.B.4    Harakeh, H.S.5    Dykes, J.K.6
  • 15
    • 0141675219 scopus 로고    scopus 로고
    • Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England
    • Andrews N., Borrow R., Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clinical and Diagnostic Laboratory Immunology 2003, 10:780-786.
    • (2003) Clinical and Diagnostic Laboratory Immunology , vol.10 , pp. 780-786
    • Andrews, N.1    Borrow, R.2    Miller, E.3
  • 16
    • 67650481170 scopus 로고    scopus 로고
    • Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs
    • Trotter C.L., Maiden M.C.J. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Review of Vaccines 2009, 8:851-861.
    • (2009) Expert Review of Vaccines , vol.8 , pp. 851-861
    • Trotter, C.L.1    Maiden, M.C.J.2
  • 18
    • 63849167605 scopus 로고    scopus 로고
    • Plasma and memory B-cell kinetics in infants following a primary schedule of CRM-conjugated serogroup C meningococcal polysaccharide vaccine
    • Kelly D.F., Snape M.D., Perrett K.P., Clutterbuck E.A., Lewis S., Rohner G.B., et al. Plasma and memory B-cell kinetics in infants following a primary schedule of CRM-conjugated serogroup C meningococcal polysaccharide vaccine. Immunology 2009, 127:134-143.
    • (2009) Immunology , vol.127 , pp. 134-143
    • Kelly, D.F.1    Snape, M.D.2    Perrett, K.P.3    Clutterbuck, E.A.4    Lewis, S.5    Rohner, G.B.6
  • 19
    • 33750629955 scopus 로고    scopus 로고
    • CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells
    • Kelly D.F., Snape M.D., Clutterbuck E.A., Green S., Snowden C., Diggle L., et al. CRM197-conjugated serogroup C meningococcal capsular polysaccharide, but not the native polysaccharide, induces persistent antigen-specific memory B cells. Blood 2006, 108:2642-2647.
    • (2006) Blood , vol.108 , pp. 2642-2647
    • Kelly, D.F.1    Snape, M.D.2    Clutterbuck, E.A.3    Green, S.4    Snowden, C.5    Diggle, L.6
  • 20
    • 34547779436 scopus 로고    scopus 로고
    • Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine
    • Centers for Disease Control and Prevention
    • Revised recommendations of the Advisory Committee on Immunization Practices to vaccinate all persons aged 11-18 years with meningococcal conjugate vaccine. MMWR - Morbidity and Mortality Weekly Report 2007, 56:794-795. Centers for Disease Control and Prevention.
    • (2007) MMWR - Morbidity and Mortality Weekly Report , vol.56 , pp. 794-795
  • 21
    • 74549171099 scopus 로고    scopus 로고
    • Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine
    • Borrow R., Andrews N., Findlow H., Waight P., Southern J., Crowley-Luke A., et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenzae type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clinical and Vaccine Immunology 2010, 17:154-159.
    • (2010) Clinical and Vaccine Immunology , vol.17 , pp. 154-159
    • Borrow, R.1    Andrews, N.2    Findlow, H.3    Waight, P.4    Southern, J.5    Crowley-Luke, A.6
  • 24
    • 0026585812 scopus 로고
    • Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group
    • Schlesinger Y., Granoff D.M. Avidity and bactericidal activity of antibody elicited by different Haemophilus influenzae type b conjugate vaccines. The Vaccine Study Group. JAMA 1992, 267:1489-1494.
    • (1992) JAMA , vol.267 , pp. 1489-1494
    • Schlesinger, Y.1    Granoff, D.M.2
  • 25
    • 0033537870 scopus 로고    scopus 로고
    • Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood
    • Anttila M., Eskola J., Ahman H., Käyhty H. Differences in the avidity of antibodies evoked by four different pneumococcal conjugate vaccines in early childhood. Vaccine 1999, 17:1970-1977.
    • (1999) Vaccine , vol.17 , pp. 1970-1977
    • Anttila, M.1    Eskola, J.2    Ahman, H.3    Käyhty, H.4
  • 26
    • 0035169929 scopus 로고    scopus 로고
    • Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers
    • Richmond P., Borrow R., Goldblatt D., Findlow J., Martin S., Morris R., et al. Ability of 3 different meningococcal C conjugate vaccines to induce immunologic memory after a single dose in UK toddlers. Journal of Infectious Diseases 2001, 183:160-163.
    • (2001) Journal of Infectious Diseases , vol.183 , pp. 160-163
    • Richmond, P.1    Borrow, R.2    Goldblatt, D.3    Findlow, J.4    Martin, S.5    Morris, R.6
  • 27
    • 66949123804 scopus 로고    scopus 로고
    • Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis
    • de Voer R.M., van der Klis F.R.M., Nooitgedagt J.E., Versteegh F.G.A., van Huisseling J.C.M., van Rooijen D.M., et al. Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis. Clinical Infectious Diseases 2009, 49:58-64.
    • (2009) Clinical Infectious Diseases , vol.49 , pp. 58-64
    • de Voer, R.M.1    van der Klis, F.R.M.2    Nooitgedagt, J.E.3    Versteegh, F.G.A.4    van Huisseling, J.C.M.5    van Rooijen, D.M.6
  • 28
    • 77957923744 scopus 로고    scopus 로고
    • Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine
    • de Voer R.M., Mollema L., Schepp R.M., de Greeff S.C., van Gageldonk P.G.M., de Melker H.E., et al. Immunity against Neisseria meningitidis serogroup C in the Dutch population before and after introduction of the meningococcal c conjugate vaccine. PLoS ONE 2010, 5:e12144.
    • (2010) PLoS ONE , vol.5
    • de Voer, R.M.1    Mollema, L.2    Schepp, R.M.3    de Greeff, S.C.4    van Gageldonk, P.G.M.5    de Melker, H.E.6
  • 31
    • 0035077458 scopus 로고    scopus 로고
    • Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains
    • Richmond P., Borrow R., Findlow J., Martin S., Thornton C., Cartwright K., et al. Evaluation of de-O-acetylated meningococcal C polysaccharide-tetanus toxoid conjugate vaccine in infancy: reactogenicity, immunogenicity, immunologic priming, and bactericidal activity against O-acetylated and de-O-acetylated serogroup C strains. Infection and Immunity 2001, 69:2378-2382.
    • (2001) Infection and Immunity , vol.69 , pp. 2378-2382
    • Richmond, P.1    Borrow, R.2    Findlow, J.3    Martin, S.4    Thornton, C.5    Cartwright, K.6
  • 32
    • 0141446167 scopus 로고    scopus 로고
    • Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom
    • Borrow R., Goldblatt D., Finn A., Southern J., Ashton L., Andrews N., et al. Immunogenicity of, and immunologic memory to, a reduced primary schedule of meningococcal C-tetanus toxoid conjugate vaccine in infants in the United kingdom. Infection and Immunity 2003, 71:5549-5555.
    • (2003) Infection and Immunity , vol.71 , pp. 5549-5555
    • Borrow, R.1    Goldblatt, D.2    Finn, A.3    Southern, J.4    Ashton, L.5    Andrews, N.6
  • 33
    • 84861526415 scopus 로고    scopus 로고
    • Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United Kingdom
    • Findlow H., Borrow R., Andrews N., Waight P., Sheasby E., Matheson M., et al. Immunogenicity of a single dose of meningococcal group C conjugate vaccine given at 3 months of age to healthy infants in the United Kingdom. Pediatric Infectious Disease Journal 2012, 31:616-622.
    • (2012) Pediatric Infectious Disease Journal , vol.31 , pp. 616-622
    • Findlow, H.1    Borrow, R.2    Andrews, N.3    Waight, P.4    Sheasby, E.5    Matheson, M.6
  • 34
    • 59649129826 scopus 로고    scopus 로고
    • Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom
    • Southern J., Borrow R., Andrews N., Morris R., Waight P., Hudson M., et al. Immunogenicity of a reduced schedule of meningococcal group C conjugate vaccine given concomitantly with the Prevenar and Pediacel vaccines in healthy infants in the United Kingdom. Clinical and Vaccine Immunology 2009, 16:194-199.
    • (2009) Clinical and Vaccine Immunology , vol.16 , pp. 194-199
    • Southern, J.1    Borrow, R.2    Andrews, N.3    Morris, R.4    Waight, P.5    Hudson, M.6
  • 35
    • 28644448593 scopus 로고    scopus 로고
    • Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine
    • Southern J., Crowley-Luke A., Borrow R., Andrews N., Miller E. Immunogenicity of one, two or three doses of a meningococcal C conjugate vaccine conjugated to tetanus toxoid, given as a three-dose primary vaccination course in UK infants at 2, 3 and 4 months of age with acellular pertussis-containing DTP/Hib vaccine. Vaccine 2006, 24:215-219.
    • (2006) Vaccine , vol.24 , pp. 215-219
    • Southern, J.1    Crowley-Luke, A.2    Borrow, R.3    Andrews, N.4    Miller, E.5
  • 36
    • 75949085277 scopus 로고    scopus 로고
    • A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months
    • Díez-Domingo J., Planelles Cantarino M.V., Baldó Torrenti J.M., Sansano M.I., Rosich A.J., Merino A.H., et al. A randomized, multicenter, open-label clinical trial to assess the immunogenicity of a meningococcal C vaccine booster dose administered to children aged 14 to 18 months. Pediatric Infectious Disease Journal 2010, 29:1-5.
    • (2010) Pediatric Infectious Disease Journal , vol.29 , pp. 1-5
    • Díez-Domingo, J.1    Planelles Cantarino, M.V.2    Baldó Torrenti, J.M.3    Sansano, M.I.4    Rosich, A.J.5    Merino, A.H.6
  • 37
    • 33746765741 scopus 로고    scopus 로고
    • Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine
    • Tejedor J.C., Moro M., Ruiz-Contreras J., Castro J., Gómez-Campderá J.A., Navarro M.L., et al. Immunogenicity and reactogenicity of primary immunization with a hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type B vaccine coadministered with two doses of a meningococcal C-tetanus toxoid conjugate vaccine. Pediatric Infectious Disease Journal 2006, 25:713-720.
    • (2006) Pediatric Infectious Disease Journal , vol.25 , pp. 713-720
    • Tejedor, J.C.1    Moro, M.2    Ruiz-Contreras, J.3    Castro, J.4    Gómez-Campderá, J.A.5    Navarro, M.L.6
  • 38
    • 50949133438 scopus 로고    scopus 로고
    • Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age
    • Tejedor J.C., Moro M., Merino J.M., Gómez-Campderá J.A., García-del-Rio M., Jurado A., et al. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup c-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age. Pediatric Infectious Disease Journal 2008, 27:579-588.
    • (2008) Pediatric Infectious Disease Journal , vol.27 , pp. 579-588
    • Tejedor, J.C.1    Moro, M.2    Merino, J.M.3    Gómez-Campderá, J.A.4    García-del-Rio, M.5    Jurado, A.6
  • 39
    • 0036838274 scopus 로고    scopus 로고
    • Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom
    • Borrow R., Goldblatt D., Andrews N., Southern J., Ashton L., Deane S., et al. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United Kingdom. Journal of Infectious Diseases 2002, 186:1353-1357.
    • (2002) Journal of Infectious Diseases , vol.186 , pp. 1353-1357
    • Borrow, R.1    Goldblatt, D.2    Andrews, N.3    Southern, J.4    Ashton, L.5    Deane, S.6
  • 40
    • 67651014413 scopus 로고    scopus 로고
    • Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine
    • Kitchin N., Southern J., Morris R., Borrow R., Fiquet A., Boisnard F., et al. Antibody persistence in UK pre-school children following primary series with an acellular pertussis-containing pentavalent vaccine given concomitantly with meningococcal group C conjugate vaccine, and response to a booster dose of an acellular pertussis-containing quadrivalent vaccine. Vaccine 2009, 27:5096-5102.
    • (2009) Vaccine , vol.27 , pp. 5096-5102
    • Kitchin, N.1    Southern, J.2    Morris, R.3    Borrow, R.4    Fiquet, A.5    Boisnard, F.6
  • 41
    • 77952993552 scopus 로고    scopus 로고
    • Antibody persistence after serogroup C meningococcal conjugate immunization of United kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial
    • Perrett K.P., Winter A.P., Kibwana E., Jin C., John T.M., Yu L.M., et al. Antibody persistence after serogroup C meningococcal conjugate immunization of United kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial. Clinical Infectious Diseases 2010, 50:1601-1610.
    • (2010) Clinical Infectious Diseases , vol.50 , pp. 1601-1610
    • Perrett, K.P.1    Winter, A.P.2    Kibwana, E.3    Jin, C.4    John, T.M.5    Yu, L.M.6
  • 42
    • 38049098648 scopus 로고    scopus 로고
    • Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial
    • Snape M.D., Perrett K.P., Ford K.J., John T.M., Pace D., Yu L.M., et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008, 299:173-184.
    • (2008) JAMA , vol.299 , pp. 173-184
    • Snape, M.D.1    Perrett, K.P.2    Ford, K.J.3    John, T.M.4    Pace, D.5    Yu, L.M.6
  • 43
    • 71249129860 scopus 로고    scopus 로고
    • A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children
    • Knuf M., Kieninger-Baum D., Habermehl P., Muttonen P., Maurer H., Vink P., et al. A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 2010, 28:744-753.
    • (2010) Vaccine , vol.28 , pp. 744-753
    • Knuf, M.1    Kieninger-Baum, D.2    Habermehl, P.3    Muttonen, P.4    Maurer, H.5    Vink, P.6
  • 44
    • 33845393967 scopus 로고    scopus 로고
    • Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom
    • Auckland C., Gray S., Borrow R., Andrews N., Goldblatt D., Ramsay M., et al. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom. Journal of Infectious Diseases 2006, 194:1745-1752.
    • (2006) Journal of Infectious Diseases , vol.194 , pp. 1745-1752
    • Auckland, C.1    Gray, S.2    Borrow, R.3    Andrews, N.4    Goldblatt, D.5    Ramsay, M.6
  • 45
    • 65549083873 scopus 로고    scopus 로고
    • Immunogenicity of fractional doses of tetravalent A/C/Y/W135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda
    • Guerin P.J., Næss L.M., Fogg C., Rosenqvist E., Pinoges L., Bajunirwe F., et al. Immunogenicity of fractional doses of tetravalent A/C/Y/W135 meningococcal polysaccharide vaccine: results from a randomized non-inferiority controlled trial in Uganda. PLOS Neglected Tropical Diseases 2008, 2:e342.
    • (2008) PLOS Neglected Tropical Diseases , vol.2
    • Guerin, P.J.1    Næss, L.M.2    Fogg, C.3    Rosenqvist, E.4    Pinoges, L.5    Bajunirwe, F.6
  • 46
    • 78650254056 scopus 로고    scopus 로고
    • Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age
    • Halperin S.A., Gupta A., Jeanfreau R., Klein N.P., Reisinger K., Walter E., et al. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine 2010, 28:7865-7872.
    • (2010) Vaccine , vol.28 , pp. 7865-7872
    • Halperin, S.A.1    Gupta, A.2    Jeanfreau, R.3    Klein, N.P.4    Reisinger, K.5    Walter, E.6
  • 47
    • 77952430892 scopus 로고    scopus 로고
    • Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers
    • Halperin S.A., Diaz M., Dull P., Anemona A., Ceddia F. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. European Journal of Clinical Microbiology and Infectious Diseases 2010, 29:259-267.
    • (2010) European Journal of Clinical Microbiology and Infectious Diseases , vol.29 , pp. 259-267
    • Halperin, S.A.1    Diaz, M.2    Dull, P.3    Anemona, A.4    Ceddia, F.5
  • 49
    • 84859005838 scopus 로고    scopus 로고
    • Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations
    • Khatami A., Snape M.D., Davis E., Layton H., John T., Yu L.M., et al. Persistence of the immune response at 5 years of age following infant immunisation with investigational quadrivalent MenACWY conjugate vaccine formulations. Vaccine 2012, 30:2831-2838.
    • (2012) Vaccine , vol.30 , pp. 2831-2838
    • Khatami, A.1    Snape, M.D.2    Davis, E.3    Layton, H.4    John, T.5    Yu, L.M.6
  • 50
    • 80055005675 scopus 로고    scopus 로고
    • Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine
    • de Whalley P.C.S., Snape M.D., Kelly D.F., Banner C., Lewis S., Diggle L., et al. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine. Pediatric Infectious Disease Journal 2011, 30:e203-e208.
    • (2011) Pediatric Infectious Disease Journal , vol.30
    • de Whalley, P.C.S.1    Snape, M.D.2    Kelly, D.F.3    Banner, C.4    Lewis, S.5    Diggle, L.6
  • 51
    • 9144241845 scopus 로고    scopus 로고
    • Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults
    • Southern J., Deane S., Ashton L., Borrow R., Goldblatt D., Andrews N., et al. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Clinical and Diagnostic Laboratory Immunology 2004, 11:1100-1104.
    • (2004) Clinical and Diagnostic Laboratory Immunology , vol.11 , pp. 1100-1104
    • Southern, J.1    Deane, S.2    Ashton, L.3    Borrow, R.4    Goldblatt, D.5    Andrews, N.6
  • 53
    • 13844254496 scopus 로고    scopus 로고
    • Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine
    • Snape M.D., Kelly D.F., Green B., Moxon E.R., Borrow R., Pollard A.J. Lack of serum bactericidal activity in preschool children two years after a single dose of serogroup C meningococcal polysaccharide-protein conjugate vaccine. Pediatric Infectious Disease Journal 2005, 24:128-131.
    • (2005) Pediatric Infectious Disease Journal , vol.24 , pp. 128-131
    • Snape, M.D.1    Kelly, D.F.2    Green, B.3    Moxon, E.R.4    Borrow, R.5    Pollard, A.J.6
  • 54
    • 77952004260 scopus 로고    scopus 로고
    • Updated post-licensure surveillance of meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlate of protection and modelling predictions of the duration of herd immunity
    • Campbell H., Andrews N., Borrow R., Trotter C., Miller E. Updated post-licensure surveillance of meningococcal C conjugate vaccine in England and Wales: effectiveness, validation of serological correlate of protection and modelling predictions of the duration of herd immunity. Clinical and Vaccine Immunology 2010, 17:840-847.
    • (2010) Clinical and Vaccine Immunology , vol.17 , pp. 840-847
    • Campbell, H.1    Andrews, N.2    Borrow, R.3    Trotter, C.4    Miller, E.5
  • 56
    • 0037172392 scopus 로고    scopus 로고
    • Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination
    • Maiden M.C.J., Stuart J.M. Carriage of serogroup C meningococci 1 year after meningococcal C conjugate polysaccharide vaccination. Lancet 2002, 359:1829-1831.
    • (2002) Lancet , vol.359 , pp. 1829-1831
    • Maiden, M.C.J.1    Stuart, J.M.2
  • 57
  • 59
    • 84883598534 scopus 로고    scopus 로고
    • Determining the appropriate age for a second immunization with meningococcal serogroup C conjugate vaccine; an intervention study among Dutch teenagers
    • Poster number: P141, in: XVIII International Pathogenic Neisseria Conference (IPNC), September 9-14, 2012, Würzburg, Germany.
    • Stoof S, van der Klis F, van Rooijen D, Sanders E, Berbers G. Determining the appropriate age for a second immunization with meningococcal serogroup C conjugate vaccine; an intervention study among Dutch teenagers. 2012; Poster number: P141, in: XVIII International Pathogenic Neisseria Conference (IPNC), September 9-14, 2012, Würzburg, Germany.
    • (2012)
    • Stoof, S.1    Van der Klis, F.2    Van Rooijen, D.3    Sanders, E.4    Berbers, G.5
  • 60
    • 33645239697 scopus 로고    scopus 로고
    • Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision
    • Cano R., Larrauri A., Mateo S., Alcalá B., Salcedo C., Vázquez J.A. Impact of the meningococcal C conjugate vaccine in Spain: an epidemiological and microbiological decision. Eurosurveillance 2004, 9:11-15.
    • (2004) Eurosurveillance , vol.9 , pp. 11-15
    • Cano, R.1    Larrauri, A.2    Mateo, S.3    Alcalá, B.4    Salcedo, C.5    Vázquez, J.A.6
  • 61
    • 0027465133 scopus 로고
    • Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization
    • Ceesay S.J., Allen S.J., Menon A., Todd J.E., Cham K., Carlone G.M., et al. Decline in meningococcal antibody levels in African children 5 years after vaccination and the lack of an effect of booster immunization. Journal of Infectious Diseases 1993, 167:1212-1216.
    • (1993) Journal of Infectious Diseases , vol.167 , pp. 1212-1216
    • Ceesay, S.J.1    Allen, S.J.2    Menon, A.3    Todd, J.E.4    Cham, K.5    Carlone, G.M.6
  • 62
    • 0032544968 scopus 로고    scopus 로고
    • Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial
    • MacDonald N.E., Halperin S.A., Law B.J., Forrest B., Danzig L.E., Granoff D.M. Induction of immunologic memory by conjugated vs plain meningococcal C polysaccharide vaccine in toddlers: a randomized controlled trial. JAMA 1998, 280:1685-1689.
    • (1998) JAMA , vol.280 , pp. 1685-1689
    • MacDonald, N.E.1    Halperin, S.A.2    Law, B.J.3    Forrest, B.4    Danzig, L.E.5    Granoff, D.M.6
  • 63
    • 9244259661 scopus 로고    scopus 로고
    • Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine
    • De Wals P., Deceuninck G., Boulianne N., de Serres G. Effectiveness of a mass immunization campaign using serogroup C meningococcal conjugate vaccine. JAMA 2004, 292:2491-2494.
    • (2004) JAMA , vol.292 , pp. 2491-2494
    • De Wals, P.1    Deceuninck, G.2    Boulianne, N.3    de Serres, G.4
  • 65
    • 21244452423 scopus 로고    scopus 로고
    • Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination
    • Trotter C.L., Gay N.J., Edmunds W.J. Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. American Journal of Epidemiology 2005, 162:89-100.
    • (2005) American Journal of Epidemiology , vol.162 , pp. 89-100
    • Trotter, C.L.1    Gay, N.J.2    Edmunds, W.J.3
  • 66
    • 84883597286 scopus 로고    scopus 로고
    • Protein-polysaccharide conjugate vaccine failure
    • 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), May 4-8, Nice, France.
    • Pollard AJ. Protein-polysaccharide conjugate vaccine failure, 2010, in: 28th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), May 4-8, 2010, Nice, France.
    • (2010)
    • Pollard, A.J.1
  • 67
    • 70349560669 scopus 로고    scopus 로고
    • Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease
    • Centers for Disease Control and Prevention
    • Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR. Morbidity and Mortality Weekly Report 2009, 58:1042-1043. Centers for Disease Control and Prevention.
    • (2009) MMWR. Morbidity and Mortality Weekly Report , vol.58 , pp. 1042-1043
  • 69
  • 70
    • 84883599192 scopus 로고    scopus 로고
    • European Medicines Agency. Bexsero. [accessed 11.03.13].
    • European Medicines Agency. Bexsero. [accessed 11.03.13]. http://www.ema.europa.eu/ema/index.jsp%3Fcurl=pages/medicines/human/medicines/002333/human_med_001614.jsp%26mid=WC0b01ac058001d124.
  • 71
    • 84879226793 scopus 로고    scopus 로고
    • Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, Nimenrix™, a review
    • Findlow H., Borrow R. Immunogenicity and safety of a meningococcal serogroup A, C, Y and W glycoconjugate vaccine, Nimenrix™, a review. Advances in Therapy 2013, 30:431-458.
    • (2013) Advances in Therapy , vol.30 , pp. 431-458
    • Findlow, H.1    Borrow, R.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.